论文部分内容阅读
伊布利特是一个新型的Ⅲ类抗心律失常药物,于1995年获美国FDA批准,1996年正式投入临床,主要用于持续3个月以内的心房扑动(房扑)和心房颤动(房颤)的转复治疗[1],随后在世界各国逐渐广泛
Ibutilide is a new Class III anti-arrhythmic drug approved by the U.S. FDA in 1995 and formally put into clinical practice in 1996. It is mainly used for atrial flutter (atrial flutter) and atrial fibrillation Fibrillation) of the recovery treatment [1], followed by gradually widening in all countries in the world